Strong Revenue and Test Volume Growth
Castle Biosciences reported Q2 2025 revenue of $86.2 million with a 33% year-over-year increase in core revenue driver test volumes. The company ended the quarter with $275.9 million in cash, cash equivalents, and marketable securities.
TissueCypher Test Performance
The TissueCypher test showed a 92% year-over-year growth with 9,170 reports in Q2 2025, up from 4,782 in Q2 2024, reflecting strong momentum in the gastroenterology franchise.
DecisionDx-Melanoma Test Success
Castle Biosciences delivered 9,981 DecisionDx-Melanoma test reports in Q2 2025, a sequential increase of 16% from Q1 2025 and a 4% year-over-year increase, marking the largest sequential increase since the IPO in 2019.
Collaborations and Pipeline Developments
Castle Biosciences entered a collaboration with SciBase to develop a diagnostic test for atopic dermatitis, with plans to launch by the end of 2025. A new genomic signature for predicting treatment response in atopic dermatitis has also been identified.
Financial Performance and Guidance
The company raised its 2025 revenue guidance to $310 million to $320 million, up from the previous range of $287 million to $297 million, reflecting strong performance and growth expectations.